NEW YORK (Associated Press) - Shares of Teva Pharmaceutical Industries Ltd. fell Friday as Momenta Pharmaceuticals Inc. turned the tables on the generic drug developer by challenging the patent on its lucrative multiple sclerosis drug. On Friday, Cambridge, Mass.-based Momenta and its partner Sandoz Inc. said the Food and Drug Administration will review an application for a generic version of Teva’s Copaxone, which is under patent protection until 2014. Israel-based Teva expects a formal patent challenge and said it will file a lawsuit to stop the companies from making a generic version.
